JAK2 and acute lymphoblastic leukemia: Eμ-Crlf2/Jak2 mutant B-ALL cells that had remained viable even weeks after knockdown of Jak2 in vivo retained leukemogenic potential and remained partially sensitive to Jak2 depletion, as shown by serial transplant experiments.